ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks.Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddressed renal lipotoxicity to attenuate renal damage and slow disease progression.Lead indication: Orphan disease FSGS (focal segmental glomerulosclerosis)Value...

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company’s program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-in-kind interleukin-2 (“IL-2”) fusion immunotherapeutic. IL-2, the active component of HCW9302, is the cytokine in humans and other vertebrates...

Company Completes Strategic Transition to Berachain-Focused Digital Asset Treasury BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq: GNLN), a publicly traded digital asset treasury company focused on the acquisition, management, and strategic deployment of BERA, the native token of the Berachain blockchain network, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Digital Asset Treasury Strategy In October 2025, following the closing of a private placement that raised $110.7M in capital, Greenlane adopted a Treasury Policy and initiated a strategic shift toward a digital asset treasury strategy focused on BERA, the native token of the Berachain blockchain network. This strategy reflects the Company’s conviction in...

Company enters 2026 with reduced leverage, extended debt maturity and added liquidity Pursues top-line stabilization and margin expansion with strategic brand repositioning to Beyond The Plant Protein Company™ EL SEGUNDO, Calif., March 31, 2026 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), otherwise known as Beyond The Plant Protein Company™ (the “Company”), today reported financial results for its fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights1Net revenues were $61.6 million, a decrease of 19.7% year-over-year. Gross profit was $1.4 million, or gross margin of 2.3%, compared to gross profit of $10.0 million, or gross margin of 13.1%, in the year-ago period.Gross profit and gross margin included $2.4 million in non-cash charges arising from incremental provision...

Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue Growth in Q2 and Full Year 2026 Recent Nasdaq Listing Under Ticker Symbol “AIDX” and New Growth Initiatives Position 20/20 BioLabs for 2026 Expansion GAITHERSBURG, Md., March 31, 2026 (GLOBE NEWSWIRE) —  20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the full year ended December 31, 2025. Fourth Quarter & Subsequent 2026 Operational HighlightsRevenue of $2.0 million for FY 2025, representing an increase...

Margin Expansion and Cost Reduction lead to Growth in Adj EBITDA ROCHESTER, NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (Nasdaq: OPTX) (“Syntec” or the “Company”), a leading provider of technology across defense, biomedical, communications, and consumer end-markets, today reported that the previously announced Company’s focus on operations efficiency had a positive impact on financial results for the fourth quarter and full year ended December 31, 2025. Q4 2025 HighlightsGross margin saw significant expansion, nearly doubling compared to the same-year previous quarter and prior-year quarter (Gross Margin for Q4 2024 was 13%, Q3 2025 was 12%, and Q4 2025 was 24%). Gross profit also saw significant improvement, increased 100% sequentially and increased 80% compared to the prior year (Gross Profit for...

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of Photonic Integrated Circuits (PICs), light sources and optical modules for the AI and data center markets, today reported its audited consolidated financial results for the fourth quarter ended December 31, 2025. The Company’s financial results as well as the Management Discussion and Analysis have been filed on SEDAR+. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Management Commentary:“In Q4 2025, we made a decisive transition from development to execution, supported by substantial capital inflows and growing commercial validation of our technology,” said POET Chairman & CEO, Dr. Suresh Venkatesan. “We secured over US$225 million...

TEL-AVIV, Israel, March 31, 2026 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, Israel and USA, today reported the publication in Israel of financial statements as of and for the year ended December 31, 2025 of Dorad Energy Ltd. (“Dorad”), in which Ellomay currently indirectly holds approximately 16.9% through its indirect 50% ownership of Ellomay Luzon Energy Infrastructures Ltd. (“Ellomay Luzon Energy”). On March 31, 2026, Amos Luzon Entrepreneurship and Energy Group Ltd. (the “Luzon Group”), an Israeli public company that currently holds the remaining 50% of Ellomay Luzon Energy, which, in turn, holds 33.75% of Dorad, published its annual report in Israel based on the requirements...

NEW YORK and TOKYO, March 31, 2026 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or the “Company”), an IPO consulting services company based in Tokyo, reported financial results for the full year ended December 31, 2025. Recent Operational HighlightsAs of March 31, 2026, HeartCore was engaged with 16 Go IPO clients, including 6 clients currently in various stages of preparation for potential public registrations and U.S. exchange listings. Authorized one-time distribution payment to stockholders. Authorized $2.0 million share repurchase program. Divested software business subsidiary, HeartCore Co., Ltd (“HeartCore Japan”). Established Higgs Field Co., Ltd. (“Higgs Field”) on October 31, 2025, as a new subsidiary in Japan to support the Company’s strategic transition toward financial services.Management...

Intermap has been down-selected for all four remaining lots of Indonesia’s ILASP Project Subscription and data revenue grew 29% year over year Strengthened balance sheet positions Company for large-scale government programs AI-enabled risk assistant gaining traction and driving growth in recurring revenue Company affirms guidance of $30–35 million in revenue with a 28% EBITDA margin DENVER, March 31, 2026 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today reported its fourth quarter and full year 2025 financial results, highlighting a strengthened balance sheet and continued growth in recurring subscription and data revenue. Intermap ended 2025 with a significantly strengthened balance sheet and continued growth...